Breaking News Instant updates and real-time market news.

WMT

Walmart

$84.80

-1.27 (-1.48%)

, CSCO

Cisco

$43.73

-1.43 (-3.17%)

12:21
05/17/18
05/17
12:21
05/17/18
12:21

On The Fly: Top stock stories at midday

Stocks opened in negative territory but the averages drifted off their lows in morning trading and eventually crossed into positive ground. The averages continue to search for direction and have turned mixed near midday, as concerns over trade talks, higher interest rates, and higher oil prices are all percolating. ECONOMIC EVENTS: In the U.S., initial jobless claims rose 11,000 to 222,000 in the week ended May 12. The Philadelphia Fed Business Outlook Survey climbed 11.2 points to a 34.4 reading, which was much stronger than expected. An index of leading economic indicators rose another 0.4% to 109.4 in April, as expected. COMPANY NEWS: Shares of Walmart (WMT) were 1.5% lower despite the company reporting better than expected results for the first quarter, with U.S. comp sales increasing 2.1% year-over-year in the period. In particular, the Dow member said that its e-commerce sales grew 33% in Q1 and that the company is on track to boost its online grocery pickup by roughly 1,000 stores this year. The retail giant noted, however, that its investment in Flipkart is expected to negatively impact fiscal 2019 earnings per share by roughly 25c-30c if the deal closes at the end of the second quarter... In other earnings news, shares of Cisco (CSCO) fell 3% after the company reported quarterly results and provided guidance for the fourth quarter. Of note, Piper Jaffray said that the only "disappointments" were the lower percentage of recurring revenue, implied recurring software product revenue, services revenue, and reported free cash flow... A day after rival Macy's (M) reported quarterly results, J.C. Penney (JCP) reported results for its fiscal Q1 but lowered its adjusted earnings guidance for fiscal 2018. J.C. Penney shares were down 11% near noon... Meanwhile, Wells Fargo (WFC) shares were 1.5% lower after the Wall Street Journal reported that employees in the bank's wholesale unit added or altered information on documents related to corporate customers without customers' knowledge in 2017 and early 2018. The Journal said that the information added varied from social security numbers to addresses to dates of birth for people associated with business-banking clients. MAJOR MOVERS: Among the noteworthy gainers was Loxo Oncology (LOXO), which jumped 19% after it released data regarding its experimental LOXO-292 cancer drug. Also higher was WWE (WWE), which gained 15% after Guggenheim analyst Curry Baker said he is "bullish" on the company's TV renewal prospects based on the terms about to be achieved by UFC. Among the notable losers was Jounce Therapeutics (JNCE), which plunged 33% after the company's report of "underwhelming" JTX2011 data ahead of the ASCO meeting led to a downgrade of the stock at Wells Fargo. Also lower was Flowers Foods (FLO), which fell 9% after reporting quarterly results. INDEXES: Near midday, the Dow was down 17.57, or 0.07%, to 24,751.36, the Nasdaq was up 5.15, or 0.07%, to 7,403.44, and the S&P 500 was up 2.48, or 0.09%, to 2,724.94.

WMT

Walmart

$84.80

-1.27 (-1.48%)

CSCO

Cisco

$43.73

-1.43 (-3.17%)

JCP

J.C. Penney

$2.74

-0.34 (-11.04%)

M

Macy's

$34.28

1.12 (3.38%)

WFC

Wells Fargo

$54.12

-0.93 (-1.69%)

LOXO

Loxo Oncology

$165.97

27.02 (19.45%)

WWE

WWE

$50.56

6.98 (16.02%)

JNCE

Jounce Therapeutics

$11.97

-5.69 (-32.22%)

FLO

Flowers Foods

$19.49

-2.13 (-9.85%)

  • 17

    May

  • 17

    May

  • 17

    May

  • 17

    May

  • 18

    May

  • 23

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 01

    Jun

  • 01

    Jun

  • 07

    Jun

  • 10

    Jul

WMT Walmart
$84.80

-1.27 (-1.48%)

05/17/18
GDHS
05/17/18
DOWNGRADE
GDHS
Accumulate
Walmart downgraded to Accumulate from Buy at Gordon Haskett
05/17/18
BARD
05/17/18
NO CHANGE
Target $95
BARD
Outperform
Walmart Q1 results all in all very positive, says Baird
Baird analyst Peter Benedict noted Walmart reported Q1 results which beat both his and Street estimates. The analyst said results were driven by higher sales and better gross margins, but noted comps were a touch light, citing seasonal trends in April. He said the results were positive overall with better sales, gross margins, and e-commerce acceleration outweighing the slight U.S. comp deceleration. Benedict reiterated his Outperform rating and $95 price target on Walmart shares.
05/16/18
MKMP
05/16/18
NO CHANGE
Target $93
MKMP
Buy
Target to benefit from strong digital sales, says MKM Partners
MKM Partners analyst Patrick McKeever kept his Buy rating and $93 price target on Target Corp (TGT) ahead of its Q1 earnings next week. The analyst says the aggressive Street consensus for earnings is "doable" in spite of the negative impact from cold weather in the East, noting that the quarter will likely see more strong growth in digital sales driven by more "expedient" fulfillment and new orders. McKeever adds that despite the 12% run in the stock price year-to-date, its valuation is still 3.4 points below that of Walmart (WMT) on "overly pessimistic" investor sentiment. The analyst says Target remains his "Top Pick" in the space in 2018.
05/15/18
SPHN
05/15/18
NO CHANGE
Target $108
SPHN
Overweight
Walmart Q1 expectations achievable, says Stephens
Stephens analyst Ben Bienvenu said he believes that consensus expectations regarding Walmart's Q1 results are achievable, though he noted that e-commerce growth in the quarter may come in below the company's annual guidance for about 40% growth. Still, easier e-commerce comparisons as the year progresses make its annual goals doable and Bienvenu remains confident that Walmart is one of the best positioned retailers he covers, he tells investors. He maintains an Overweight rating and $108 price target on Walmart ahead of the company's earnings report due on Thursday.
CSCO Cisco
$43.73

-1.43 (-3.17%)

05/17/18
JMPS
05/17/18
NO CHANGE
JMPS
Market Perform
Cisco results bode well for Arista, Nutanix and Palo Alto, says JMP Securities
JMP Securities analyst Erik Suppiger said Cisco (CSCO) noted strength in data center and campus switching in its Q3 earnings report, which suggests to him that demand trends are favorable for Arista Networks (ANET). In the DC business, Cisco noted it grew double digits year-over-year driven by its hyperconverged infrastructure product, which Suppiger sees pointing to favorable demand for Nutanix (NTNX). Additionally, security sales re-accelerated in the quarter to double-digit growth for the first time in over a year, which the analyst reads as a favorable trend for Palo Alto Networks (PANW). On Cisco itself, Suppiger said he sees the stock as fairly valued and he maintains a Market Perform rating on the shares.
05/17/18
MSCO
05/17/18
NO CHANGE
Target $50
MSCO
Overweight
Cisco laying groundwork for upside in FY19, says Morgan Stanley
Following Cisco's report of "strong" Q3 results and "generally positive" comments from management regarding the outlook, Morgan Stanley analyst James Faucette said the earnings call "offered ample evidence" Cisco's software strategy is progressing well. He sees software helping to stabilize equipment replacement cycles and believes the stock will approach $50 as the market becomes more convinced FY19 estimates are too low. Faucette maintains an Overweight rating and $50 price target on Cisco shares.
05/17/18
RBCM
05/17/18
NO CHANGE
Target $50
RBCM
Outperform
Cisco post-earnings stock dip is a buying opportunity, says RBC Capital
RBC Capital analyst Mitch Steves kept his Outperform rating and $50 price target on Cisco, saying the slight pullback in the stock price following the in-line earnings and guidance may be a buying opportunity. The analyst cites continued growth in deferred revenues while also forecasting growth in Switching sales for 2-3 quarters given the backlog and its high margin levels. Steves also notes Cisco's history of buybacks when its stock price traded in $42-$44 per share range, creating a "nice support for the stock".
05/17/18
BARD
05/17/18
NO CHANGE
Target $51
BARD
Outperform
Cisco weakness a buying opportunity, says Baird
Baird analyst Jayson Noland said Cisco posted a solid quarter on nearly all metrics and recommended buying the dip in the shares. The analyst said the selloff was due in part to high expectations against its in-line Q4 guidance. Noland reiterated his Outperform rating and $51 price target on Cisco shares.
JCP J.C. Penney
$2.74

-0.34 (-11.04%)

12/22/17
MSCO
12/22/17
NO CHANGE
MSCO
TJX stands to benefit from Bon-Ton closures, says Morgan Stanley
After analyzing which department stores and off-price retailers have the greatest overlap with troubled retailer Bon-Ton Stores (BONT), Morgan Stanley analyst Kimberly Greenberger found that over 40% of Bon-Ton's have a TJX (TJX) concept within a one mile radius and she sees it as the retailer that could benefit the most from a Bon-Ton liquidity event. Though Sears (SHLD) has the greatest overlap overall, there is no evidence to suggest it, nor Kohl's (KSS) and J.C. Penney (JCP), have been able to capitalize on Bon-Ton's struggles so far, added Greenberger.
04/19/18
MSCO
04/19/18
NO CHANGE
Target $1550
MSCO
Overweight
Amazon gaining apparel market share in U.S., says Morgan Stanley
Morgan Stanley analyst Brian Nowak said his analysis shows that Amazon (AMZN) gained 1.5% of U.S. apparel market share in 2017, largely at the expense of department stores. He estimates Amazon is the second largest U.S. apparel retailer, trailing only Walmart (WMT), and expects the e-commerce giant to take the number one spot in terms of U.S. apparel market share in 2018. Cumulatively, Nowak estimates Sears (SHLD), Macy's (M) and J.C. Penney (JCP) lost 0.8% share in 2017, with shareholdings remaining roughly flat for Target (TGT) and Kohl's (KSS). He maintains an Overweight rating and $1,550 price target on Amazon shares.
11/30/17
COWN
11/30/17
NO CHANGE
Target $4
COWN
Market Perform
J.C. Penney taking steps toward a comeback, says Cowen
Cowen analyst Oliver Chen met with J.C. Penney and said he is confident the company's liquidity, its multi-year ability to drive free cash flow, and controlled capital expenditures will mitigate some risk. He likes management's simplification of marketing, its value messaging and execution, and leveraging of non-apparel categories, which should drive greater consistency in traffic and growth. Chen maintains his Market Perform rating and $4 price target on J.C. Penney shares as he looks for visibility on greater consistency in traffic trends.
03/12/18
FBCO
03/12/18
INITIATION
Target $2.5
FBCO
Underperform
J.C. Penney initiated with an Underperform at Credit Suisse
Credit Suisse initiated J.C. Penney with an Underperform and $2.50 price target.
M Macy's
$34.28

1.12 (3.38%)

05/17/18
MSCO
05/17/18
NO CHANGE
Target $25
MSCO
Underweight
Macy's may find it hard to meet raised expectations, says Morgan Stanley
Morgan Stanley analyst Kimberly Greenberger said Macy's raised 2018 guidance rests on second half performance and she remains skeptical given the more difficult comps it will be facing, particularly in the fourth quarter of the year. Greenberger raised her 2018 EPS estimate by 12c to $3.67, but notes this is still below the company's revised $3.75-$3.95 guidance range. Following the stock's more than 10% jump yesterday on the heels of the quarterly report, Greenberger keeps an Underweight rating and $25 price target on Macy's shares.
05/17/18
RBCM
05/17/18
NO CHANGE
Target $35
RBCM
Sector Perform
Macy's price target raised to $35 from $31 at RBC Capital
RBC Capital analyst Brian Tunick raised his price target on Macy's (M) to $35 after its Q1 results, saying the company's business improvements that stabilized low-single-digit comps were encouraging while margins also appear to be bottoming. Tunick also cites "favorable consumer spending" and progress on strategic initiatives driving sequential improvement in comps. The analyst keeps his Sector Perform rating however, saying the stock price will likely remain range-bound without a "meaningful" comp acceleration amid the persistent investor concerns with the impact of Amazon (AMZN) on retail and the slowing mall traffic.
05/17/18
SBSH
05/17/18
NO CHANGE
Target $25
SBSH
Sell
Macy's Q1 results 'as good as it gets,' says Citi
Citi analyst Paul Lejuez says Macy's Q1 results yesterday is "as good as it gets." Comparisons get tougher as the year progresses, Lejuez tells investors in a post-earnings research note. He notes that when stripping away the benefit from the shift in the Friends & Family promotion, the underlying comp trend in Q1 was very similar to Q4 on an absolute basis and worse than Q4 on a stacked basis. The analyst raised his price target for Macy's shares to $25 from $21 and keeps a Sell rating on the name.
05/16/18
JEFF
05/16/18
NO CHANGE
Target $30
JEFF
Hold
Jefferies ups Macy's target to $30, says read-through positive for retail peers
Jefferies analyst Randal Konik said he liked Macy's (M) "robust" revenue growth, clean inventories and controlled markdowns in the first quarter, though he also noted that Q2 comparable sales are expected to be down given the Friends and Family shift that aided Q1. Following the earnings report, Konik raised his price target on Macy's shares to $30 from $27, but he keeps a Hold rating on the stock, citing secular pressures impacting the company and the industry. The analyst, who thinks Macy's report has a positive read-through for retail more broadly, continues to prefer Kohl's (KSS), citing its off-mall positioning, differentiated assortment, and "omni-channel leadership."
WFC Wells Fargo
$54.12

-0.93 (-1.69%)

04/16/18
BARD
04/16/18
NO CHANGE
Target $62
BARD
Outperform
Lower expectations limit Wells Fargo downside, says Baird
Baird analyst David George said Wells Fargo reported messy Q1 results, but lowered expectations should limit the downside in the shares. The analyst said core fees were weak, but expenses were in line as was loan growth. George maintained his Outperform rating and $62 price target on Wells Fargo shares.
04/17/18
BMOC
04/17/18
NO CHANGE
Target $34
BMOC
Market Perform
Bank of America is the best of the 'big four' U.S. banks, says BMO Capital
BMO Capital analyst James Fotheringham kept his Market Perform rating and $34 price target on Bank of America (BAC) after its in-line Q1 earnings but raised his FY18 EPS view to $2.62 from $2.59 and FY19 view to $3.18 from $3.12. Fotheringham says than in contrast, he lowered earnings forecasts for JPMorgan (JPM), Wells Fargo (WFC), and Citigroup (C) because of higher costs and lower revenues, but Bank of America's better than expected net interest income rise justifies his view of the bank as the "best of the bunch". The analyst also notes the bank's more favorable valuation trading at a below-average two-year-forward P/E multiple despite his forecast of double the core earnings growth rate of Bank of America's peers.
04/30/18
04/30/18
UPGRADE

Outperform
Wells Fargo double upgraded to Outperform at Macquarie
Macquarie analyst David Konrad upgraded Wells Fargo to Outperform from Underperform with a $61 price target citing attractive valuation, low expectations, and near-term catalysts. Konrad said valuation and consensus estimates have finally come down and said shares are trading at 11.3x his 2019 "stressed earnings" estimate, compared to super regionals trading at 12.3x. The analyst expects low expense guidance at the upcoming investor day and passing CCAR in June to serve as positive catalysts for shares.
04/16/18
NOMU
04/16/18
NO CHANGE
Target $68
NOMU
Buy
Wells Fargo earnings underwhelming, but not a value trap, says Nomura
Nomura Instinet analyst Bill Carcache lowered his price target for Wells Fargo to $68 from $72 saying Friday's earnings results were "underwhelming" as the company reported softer revenue growth. The analyst, however, continues to believe that shares of Wells Fargo are "not a value trap." Shareholders "able to weather the current storm" will be rewarded with 10% earnings growth, mid- to high-teens return on tangible equity, and a multiple rerating when the market regains confidence, Carcache tells investors in a research note. He keeps a Buy rating on the shares.
LOXO Loxo Oncology
$165.97

27.02 (19.45%)

05/17/18
STFL
05/17/18
NO CHANGE
Target $190
STFL
Buy
Loxo Oncology price target raised to $190 after ASCO abstracts at Stifel
Stifel analyst Stephen Willey said he believes the preliminary efficacy data on Loxo Oncology's (LOXO) LOXO-292 that was reported in abstracts released last night in anticipation of the ASCO meeting should further distance the candidate from other competitive RET inhibitors. The overall response rate, or ORR, of 52% reported for the 46 evaluable patients harboring RET-altered tumors tops the 46% ORR previously-reported for competitor Blueprint Medicines' (BPMC) BLU-667 at AACR, noted Willey. The analyst, who also thinks the disclosure of this data increases visibility for potential strategic buyers who have historically shown a "willingness to pay top-dollar for long-duration targeted oncology agents," increased his price target on Loxo to $190 from $145 and keeps a Buy rating on the shares.
05/09/18
JMPS
05/09/18
NO CHANGE
Target $152
JMPS
Outperform
Loxo Oncology price target increased to $152 from $95 at JMP Securities
JMP Securities analyst Konstantinos Aprilakis raised his price target on Loxo Oncology to $152 from $95 following an update to his financial model after the company's Q1 earnings report, which he said highlighted its pipeline progress. He maintains an Outperform rating on Loxo shares.
04/16/18
04/16/18
UPGRADE
Target $170

Overweight
Loxo Oncology upgraded to Overweight after competitor data at Morgan Stanley
As previously reported, Morgan Stanley analyst Matthew Harrison upgraded Loxo Oncology (LOXO) to Overweight from Equal Weight after competitor Blueprint Medicines (BPMC) provided initial data at the AACR meeting on its RET inhibitor BLU-667 that he believes was at the lower-end of Loxo investors' expectations from a competition standpoint. He now believes Loxo has an opportunity to demonstrate differentiation on both efficacy and safety for LOXO-292 versus BLU-667 when updated data are presented at the ASCO meeting in June. Harrison, who sees the most opportunity for LOXO-292 being a better adverse effect profile, raised his price target on Loxo shares to $170 from $130.
04/16/18
STFL
04/16/18
NO CHANGE
STFL
Buy
Blueprint data leaves 'door wide open' for Loxo's LOXO-292, says Stifel
Stifel analyst Stephen Willey noted that Blueprint Medicines (BPMC) reported data from the dose-escalation portion of its Phase 1 trial of BLU-667 at this weekend's AACR meeting. He believes BLU-667 looks like "a sufficiently viable asset for RET-altered tumors," but he also thinks the data has left the competitive window "wide-open" for Loxo Oncology (LOXO) ahead of preliminary LOXO-292 data expected at the ASCO meeting in June. Loxo's data now potentially could shift sentiment on what consensus has been presuming to be a $1B+ opportunity equally-shared between the two companies, Willey tells investors. He maintains a Buy rating on Loxo shares.
WWE WWE
$50.56

6.98 (16.02%)

05/17/18
GUGG
05/17/18
NO CHANGE
Target $48
GUGG
Buy
WWE likely to see 'favorable' TV deal renewal terms, says Guggenheim
Guggenheim analyst Curry Baker is keeping his Buy rating and $48 price target on WWE, saying he is "bullish" on the company's TV renewal prospects based on the terms about to be achieved by UFC. Baker says UFC is "on the verge" of renewing its TV right at over $350M in average annual value, which he calls a "baseline minimum" for WWE considering that its RAW and SmackDown programs provide more hours of content - 260 vs. UFC's 105 - and at much higher TV ratings than UFC.
05/04/18
05/04/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Fluor (FLR) downgraded to Neutral from Outperform at Baird with analyst Andrew Wittmann saying his thesis was based on the early stage commodity cycle recovery and now he sees too few catalysts remaining in a difficult environment for industrials. 2. Diebold (DBD) downgraded to Neutral from Outperform at Credit Suisse with analyst Paul Condra saying he expects a longer turnaround to the story, and prefers a wait-and-see approach as the company's management team moves forward with another round of restructuring initiatives, the details of which have not yet been announced. 3. AMN Healthcare (AMN) downgraded to Neutral from Outperform at Baird with analyst Mark Marcon saying the boost from premium rate assignments appear to be slowing. 4. WWE (WWE) downgraded to Hold from Buy at Benchmark with analyst Mike Hickey citing valuation after the stock's 109% rise over the last year. 5. Colfax (CFX) downgraded to Sector Perform from Outperform at RBC Capital with analyst Seth Weber citing material inflation in the A&GH segment, pressuring continued expansion in margins and organic revenue growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/04/18
SBSH
05/04/18
NO CHANGE
Target $43
SBSH
Neutral
WWE price target raised to $43 from $33 at Citi
Citi analyst Jason Bazinet raised his price target for WWE to $43 citing increased TV rights forecasts. The stock is allying as investors await announcements on TV rights renewals, Bazinet tells investors in a research note. At $41 per share, the market is pricing an 80% step up in TV rights, which is possible, the analyst estimates. He notes that average sports step up is 50%. The analyst keeps a Neutral rating on WWE.
05/04/18
BNCH
05/04/18
DOWNGRADE
BNCH
Hold
WWE downgraded to Hold from Buy at Benchmark
Benchmark analyst Mike Hickey downgraded WWE to Hold from Buy citing valuation after the stock's 109% rise over the last year. Investor speculation is net positive on the company's upcoming TV rights fee negotiations, Hickey added.
JNCE Jounce Therapeutics
$11.97

-5.69 (-32.22%)

05/17/18
HCWC
05/17/18
NO CHANGE
Target $19
HCWC
Buy
Jounce Therapeutics price target lowered to $19 from $33 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Jounce Therapeutics to $19 citing the "limited activity on show" for JTX-2011, either as a monotherapy or when used in combination with Opdivo. With the stock already down today, "a reactionary downgrade here would make little sense," Chattopadhyay tells investors in a research note. He keeps a Buy rating on the shares.
05/17/18
05/17/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Molson Coors (TAP) downgraded to Hold from Buy at Stifel with analyst Mark Swartzberg saying he sees multiple expansion as unlikely because U.S. beer industry volume trends are getting worse, the company's U.S. share trends are not improving, and demographics favor continued pressure on per capita alcohol consumption. 2. Progressive (PGR) downgraded to Market Perform from Outperform at Keefe Bruyette with analyst Meyer Shields citing valuation. 3. CBS (CBS) downgraded to Neutral from Buy at BofA/Merrill with analyst Jessica Reif saying the lawsuit brought by CBS and the special committee alleging a breach of fiduciary duty by the National Amusements Inc. is a significant overhang for shares and will constrain outperformance until a ruling. 4. Canadian National (CNI) downgraded to Neutral on valuation at Macquarie with analyst Konark Gupta citing valuation. 5. Jounce Therapeutics (JNCE) downgraded to Market Perform from Outperform at Wells Fargo with analyst Jim Birchenough saying overall response rates for JTX-2011 monotherapy in gastric cancer and in triple negative breast cancer, as well as for JTX-2011 plus Opdivo in gastric cancer and in triple negative breast cancer are "underwhelming" and "not competitive with other investigational drugs." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/17/18
WELS
05/17/18
DOWNGRADE
WELS
Market Perform
Jounce Therapeutics downgraded to Market Perform from Outperform at Wells Fargo
05/17/18
WELS
05/17/18
DOWNGRADE
Target $13
WELS
Market Perform
Wells Fargo downgrades Jounce on 'underwhelming' JTX2011 data
Wells Fargo analyst Jim Birchenough downgraded Jounce Therapeutics to Market Perform from Outperform and cut his price target for the shares to $13 from $37. The stock in premarket trading is down 31%, or $5.43, to $12.24. Overall response rates for JTX-2011 monotherapy in gastric cancer and in triple negative breast cancer, as well as for JTX-2011 plus Opdivo in gastric cancer and in triple negative breast cancer are "underwhelming" and "not competitive with other investigational drugs," Birchenough tells investors in a research note following review of the ASCO abstract. He advises taking a "wait and see approach to assess strength of aggregate data."
FLO Flowers Foods
$19.49

-2.13 (-9.85%)

04/17/18
DBAB
04/17/18
INITIATION
Target $24
DBAB
Hold
Flowers Foods resumed with a Hold at Deutsche Bank
Deutsche Bank analyst Rob Dickerson resumed coverage of Flowers Foods with a Hold rating and $24 price target. The analyst believes much of the near-term upside is already priced into the stock.
04/03/18
HDLY
04/03/18
INITIATION
Target $25
HDLY
Long-Term Buy
Flowers Foods initiated with a Long-Term Buy at Hilliard Lyons
Hilliard Lyons analyst Jeffrey Thomison started Flowers Foods with a Long-term Buy rating, saying he considers it a well-run, high-quality operator that he thinks will see earnings growth return in 2018. He set a two-year price target of $25 on the stock.
04/17/18
04/17/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. GrubHub (GRUB) initiated with an Overweight at Stephens. 2. Dropbox (DBX) initiated with an Outperform at Macquarie and JMP Securities, an Overweight at KeyBanc, JPMorgan, and Piper Jaffray, a Buy at Canaccord and Deutsche Bank, a Sector Perform at RBC Capital, a Neutral at BofA/Merrill and Goldman Sachs, as well as a Hold at Jefferies. 3. Oneok (OKE) initiated with a Neutral at Seaport Global. 4. Jeld-Wen (JELD) initiated with a Hold at Jefferies. 5. Flowers Foods (FLO) resumed with a Hold at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/27/18
KEYB
03/27/18
INITIATION
Target $24
KEYB
Overweight
Flowers Foods initiated with an Overweight at KeyBanc
KeyBanc analyst David Carlson started Flowers Foods with an Overweight rating and $24 price target. The analyst sees good visibility for fiscal 2018 and believes the share reflect low expectations on the company's long-term plan.

TODAY'S FREE FLY STORIES

CMCSA

Comcast

$37.91

0.1 (0.26%)

, CMCSK

Comcast

$0.00

(0.00%)

14:32
09/22/18
09/22
14:32
09/22/18
14:32
Periodicals
Comcast outbids Fox in battle for Sky, Reuters reports »

Comcast (CMCSA; CMCSK)…

CMCSA

Comcast

$37.91

0.1 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

FOX

21st Century Fox

$43.97

-0.23 (-0.52%)

FOXA

21st Century Fox

$44.33

-0.26 (-0.58%)

SKYAY

Sky

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOKF

BOK Financial

$104.69

-0.08 (-0.08%)

, COBZ

CoBiz Financial

$23.44

0.01 (0.04%)

13:36
09/22/18
09/22
13:36
09/22/18
13:36
Conference/Events
CoBiz Financial to host special shareholder meeting »

Special Shareholder…

BOKF

BOK Financial

$104.69

-0.08 (-0.08%)

COBZ

CoBiz Financial

$23.44

0.01 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Sep

AMRH

AMERI Holdings

$1.44

-0.04 (-2.70%)

13:30
09/22/18
09/22
13:30
09/22/18
13:30
Conference/Events
AMERI Holdings to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

BRK.A

Berkshire Hathaway

$331,710.00

-1090 (-0.33%)

13:26
09/22/18
09/22
13:26
09/22/18
13:26
Periodicals
Berkshire Hathaway still looks underpriced, Barron's says »

Class A shares of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLGO

BioLargo

$0.00

(0.00%)

13:11
09/22/18
09/22
13:11
09/22/18
13:11
Conference/Events
BioLargo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZWI

Citizens Community Bancorp

$14.13

0.03 (0.21%)

12:56
09/22/18
09/22
12:56
09/22/18
12:56
Conference/Events
Citizens Community Bancorp to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SF

Stifel Financial

$54.86

-0.78 (-1.40%)

12:50
09/22/18
09/22
12:50
09/22/18
12:50
Conference/Events
Stifel Financial to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBCT

People's United

$17.94

-0.055 (-0.31%)

, FBNK

First Connecticut

$30.95

0.1 (0.32%)

12:47
09/22/18
09/22
12:47
09/22/18
12:47
Conference/Events
First Connecticut to host special shareholder meeting »

Special shareholder…

PBCT

People's United

$17.94

-0.055 (-0.31%)

FBNK

First Connecticut

$30.95

0.1 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 18

    Oct

ASPS

Altisource

$34.10

-0.09 (-0.26%)

12:44
09/22/18
09/22
12:44
09/22/18
12:44
Conference/Events
Altisource to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.65

-2.35 (-1.07%)

, CSCO

Cisco

$48.51

0.77 (1.61%)

12:36
09/22/18
09/22
12:36
09/22/18
12:36
Periodicals
Apple, Microsoft among stocks with solid dividends, Barron's says »

Technology stocks are not…

AAPL

Apple

$217.65

-2.35 (-1.07%)

CSCO

Cisco

$48.51

0.77 (1.61%)

IBM

IBM

$151.29

0.12 (0.08%)

MSFT

Microsoft

$114.70

1.13 (0.99%)

ORCL

Oracle

$51.08

0.65 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 03

    Oct

  • 04

    Oct

  • 05

    Oct

  • 10

    Oct

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Nov

  • 03

    Mar

CAT

Caterpillar

$156.39

0.38 (0.24%)

, AMAT

Applied Materials

$39.62

0.22 (0.56%)

12:28
09/22/18
09/22
12:28
09/22/18
12:28
Periodicals
Caterpillar, KeyCorp among stocks to buy as bond yields rise, Barron's says »

As the economy improves,…

CAT

Caterpillar

$156.39

0.38 (0.24%)

AMAT

Applied Materials

$39.62

0.22 (0.56%)

BWA

BorgWarner

$45.24

-0.53 (-1.16%)

KEY

KeyCorp

$20.78

0.02 (0.10%)

PH

Parker-Hannifin

$190.52

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

  • 18

    Oct

  • 25

    Oct

  • 30

    Oct

BSX

Boston Scientific

$37.76

-0.07 (-0.19%)

, ISRG

Intuitive Surgical

$556.70

-4.43 (-0.79%)

10:34
09/22/18
09/22
10:34
09/22/18
10:34
Periodicals
'Good time' to think about device markers, Barron's says »

Medical technology stocks…

BSX

Boston Scientific

$37.76

-0.07 (-0.19%)

ISRG

Intuitive Surgical

$556.70

-4.43 (-0.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

TLRY

Tilray

$123.16

-53.365 (-30.23%)

10:20
09/22/18
09/22
10:20
09/22/18
10:20
Periodicals
Marijuana stocks 'the new Bitcoin,' Barron's says »

Led by Tilray, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.65

-2.35 (-1.07%)

, WMT

Walmart

$95.85

0.1 (0.10%)

09:05
09/22/18
09/22
09:05
09/22/18
09:05
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$217.65

-2.35 (-1.07%)

WMT

Walmart

$95.85

0.1 (0.10%)

DE

Deere

$152.82

-1.24 (-0.80%)

AGCO

Agco

$60.24

-0.9 (-1.47%)

ADM

Archer Daniels

$50.33

(0.00%)

MOS

Mosaic

$32.33

0.02 (0.06%)

CF

CF Industries

$52.82

-0.48 (-0.90%)

SPWR

SunPower

$7.88

-0.18 (-2.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 28

    Oct

  • 06

    Nov

  • 13

    Nov

  • 15

    Nov

  • 03

    Mar

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

, AGN

Allergan

$191.34

-1.11 (-0.58%)

04:55
09/22/18
09/22
04:55
09/22/18
04:55
Conference/Events
European Society of Retina Specialists to hold a conference »

18th Congress of EURETINA…

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

AGN

Allergan

$191.34

-1.11 (-0.58%)

ALIM

Alimera Sciences

$1.07

(0.00%)

BABY

Natus Medical

$34.45

-0.2 (-0.58%)

BHC

Bausch Health

$24.92

-0.07 (-0.28%)

BAYRY

Bayer

$0.00

(0.00%)

ELXMF

Ellex Medical Lasers

$0.00

(0.00%)

GKOS

Glaukos

$58.78

-1.69 (-2.79%)

IRIX

IRIDEX

$6.52

0.08 (1.24%)

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

NITE

Nightstar Therapeutics

$25.64

-1.71 (-6.25%)

NVS

Novartis

$85.46

-0.505 (-0.59%)

OCUL

Ocular Therapeutix

$6.45

0.03 (0.47%)

RHHBY

Roche

$0.00

(0.00%)

SHPG

Shire

$178.32

-1.68 (-0.93%)

STAA

STAAR Surgical

$47.00

-0.9 (-1.88%)

TMDI

Titan Medical

$2.24

0.02 (0.90%)

TTNP

Titan Pharmaceuticals

$0.22

-0.2833 (-56.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 03

    Oct

  • 09

    Oct

  • 16

    Oct

  • 22

    Oct

  • 28

    Oct

  • 29

    Oct

  • 15

    Nov

  • 27

    Nov

  • 21

    Dec

  • 28

    Dec

  • 15

    Feb

  • 25

    Feb

CDTI

CDTi

$0.34

0.01 (3.08%)

18:15
09/21/18
09/21
18:15
09/21/18
18:15
Hot Stocks
CDTi sees September 21 as effective date of reverse stock split »

CDTi Advanced Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUK

Duke Energy

$79.82

-0.81 (-1.00%)

18:08
09/21/18
09/21
18:08
09/21/18
18:08
Hot Stocks
Duke Energy restored nearly 1.8M outages in NC, SC during past week »

Duke Energy crews today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 11

    Nov

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

18:01
09/21/18
09/21
18:01
09/21/18
18:01
Hot Stocks
Johnson & Johnson's Janssen discloses phase 3 study results of Esketamine »

The Janssen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 28

    Oct

UAL

United Continental

$89.94

0.8 (0.90%)

17:39
09/21/18
09/21
17:39
09/21/18
17:39
Periodicals
United pilots refuse contract changes on regional routes, Reuters says »

United Airlines pilots…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

, XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

17:36
09/21/18
09/21
17:36
09/21/18
17:36
General news
Week ending ETF Scorecard: Materials outperform, Utlilites slump »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

IYR

DJ US Real Estate Index Fund

$81.88

-0.06 (-0.07%)

XLP

Consumer Staples Sector SPDR

$55.02

0.1285 (0.23%)

XLY

Consumer Discretionary Sector SPDR

$116.98

-0.4288 (-0.37%)

XLB

S&P Select Materials SPDR

$60.54

-0.1312 (-0.22%)

XLF

Financial Select Sector

$28.73

-0.1175 (-0.41%)

XLV

Health Care Select Sector SPDR

$94.26

0.1571 (0.17%)

XLK

Technology Select Sector SPDR

$74.68

-0.2056 (-0.27%)

XLI

Industrial Select Sector SPDR

$79.71

0.2338 (0.29%)

GLD

SPDR Gold Trust

$113.48

-0.77 (-0.67%)

SLV

iShares Silver Trust

$13.44

-0.01 (-0.07%)

USO

United States Oil Fund

$14.95

0.145 (0.98%)

UNG

United States Natural Gas Fund

$24.60

0.235 (0.96%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.24

0.05 (0.06%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$114.72

0.04 (0.03%)

TLT

iShares 20+ Year Treasury Bond Fund

$117.12

-0.02 (-0.02%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.00

0.03 (0.03%)

SHY

iShares 1-3 Year Treasury Bond

$83.05

0.02 (0.02%)

IWD

iShares Russell 1000 Value

$129.51

0.13 (0.10%)

IWF

iShares Russell 1000 Growth

$155.30

-0.55 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHGI

One Horizon Group

$0.18

-0.0088 (-4.63%)

17:34
09/21/18
09/21
17:34
09/21/18
17:34
Syndicate
Breaking Syndicate news story on One Horizon Group »

One Horizon Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTX

Cytori Therapeutics

$0.41

-0.033 (-7.38%)

17:31
09/21/18
09/21
17:31
09/21/18
17:31
Syndicate
Breaking Syndicate news story on Cytori Therapeutics »

Cytori Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEM

Newmont Mining

$31.56

0.05 (0.16%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Syndicate
Breaking Syndicate news story on Newmont Mining »

Newmont Mining files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Oct

CB

Chubb

$139.87

-0.05 (-0.04%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Hot Stocks
Chubb CEO Greenberg sells $8.6M in common stock »

Chubb CEO Evan Greenberg…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTVT

vTv Therapeutics

$0.80

0.0096 (1.21%)

17:21
09/21/18
09/21
17:21
09/21/18
17:21
Hot Stocks
vTv says FDA advised that azeliragon efficacy be shown in at least 2 trials »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.